Article Text

PDF

Oral nalmefene reduced relapse to heavy drinking and was well tolerated in patients with alcohol dependence
  1. Jonathan Chick, MA, MPhil, FRCPE, FRCPsych
  1. Royal Edinburgh Hospital Edinburgh, UK

    Statistics from Altmetric.com

    
 
 QUESTION: In patients with alcohol dependence is nalmefene effective and safe?

    Design

    Randomised (unclear allocation concealment*), blinded (patients and outcome assessors,*) placebo controlled trial with 12 weeks of follow up.

    Setting

    The Alcohol Disorders Research Clinic, Jackson Memorial Medical Center, Miami, Florida, USA.

    Patients

    105 outpatients (mean age 42 y, 68% men) with a DSM-III-R diagnosis of current alcohol dependence recruited through advertisements and press releases. Exclusion criteria included dependence on illicit drugs; current use of naltrexone, disulfiram, medication containing narcotics, or psychotropic medications; notable medical or psychiatric disorders; considerable hepatocellular injury; and pregnancy. Patients were abstinent for a mean of 2 weeks before randomisation.

    Intervention

    Patients were assigned to oral nalmefene at a dose of 20 mg/day (10 mg twice daily) or 80 mg/day (40 mg twice daily) (n=70), or placebo (n=35). All patients received individual, manual guided, cognitive behavioural therapy (CTB), as used in project MATCH (Matching Alcohol Treatments to Client Heterogenetics).

    Main outcome measures

    Rate of relapse to heavy drinking (defined as ≥6 drinks consumed/d for men and ≥4 drinks/d for women), percentage of days abstinent, and change in the number of standard drinks consumed each drinking day over the 12 week follow up period.

    Main results

    Outcomes did not differ between the 20 and 80 mg dose nalmefene groups and therefore these groups were combined in the intention to treat analyses. At the first weekly study visit, fewer patients in the nalmefene group reported any heavy drinking days compared with those in the placebo group (p<0.02) (table). Fewer patients in the nalmefene group relapsed to heavy drinking over 12 weeks of treatment than those in the placebo group (p<0.02) (table). No differences existed for percentage of abstinent days or mean number of drinks consumed each drinking day. No medically serious adverse drug experiences were reported.

    Nalmefene v placebo for alcohol dependence†

    Conclusion

    Oral nalmefene reduced relapse to heavy drinking and was well tolerated in patients with alcohol dependence.

    Commentary

    The study by Mason et al supports the role of opioid antagonists in preventing alcoholic relapse, although not in maintaining complete abstinence. CBT was provided. Studies evaluating the effectiveness of the opioid antagonist naltrexone find it to be more effective in conjunction with CBT than with supportive treatment.1 Rather than emphasising the absoluteness of total abstinence and avoidance of high risk situations, CBT helps the patient to cope with those situations by teaching new skills, problem solving techniques, and survival steps to follow if a drink is taken. Volpicelli et al found that naltrexone prevented relapse more often in patients who had drunk at least some alcohol.2 Sinclair proposed that opioid antagonists assist by enabling gradual extinction of the rewarding effects of alcohol.3 In the study by Mason et al nalmefene is seen to be effective in the first week; repeated drinking while on the drug is not needed for at least some effect to emerge.

    Poor compliance with naltrexone prevents its benefits from emerging.4 Mason et al measured compliance by providing tablets in containers with microelectronic recorders, which may have helped them to achieve such high compliance rates.

    In this study we are not told what the patients' goals were (abstinence or “controlled drinking”) or what the patients were told about the putative mechanism of the effect of nalmefene. For extrapolation to routine practice, it would be helpful to know this.

    References

    View Abstract

    Footnotes

    • Source of funding: in part, National Institute on Alcohol abuse and Alcoholism; the study drugs were provided by Ivax Corporation, Miami, FL, USA.

    • For correspondence: Dr B J Mason, University of Miami, Department of Psychiatry, Alcohol Disorders Research Unit, 1400 NW 10th Avenue, Suite 307A, Miami, FL 33136, USA. Fax +1 305 243 2599.

    • * See glossary.

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.